{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:18Z","timestamp":1790419158804,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["17640"],"award-info":[{"award-number":["17640"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir\/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7\u2009days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6\u2009days; <jats:italic>P<\/jats:italic>\u2009=\u20090.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1\u2009days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) (<jats:italic>P<\/jats:italic>\u2009=\u20090.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/irct.ir\/search\/result?query=Evaluation+of+the+effect+of+Arbidol+drug+in+the+treatment+of+hospitalized+patients+with+COVID-19\">IRCT20180725040596N2<\/jats:ext-link> on 18 April 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05698-w","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T11:04:45Z","timestamp":1607943885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Marzieh","family":"Nojomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin Jamshidi","family":"Makiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Roham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Laali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Navaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"5698_CR1","unstructured":"World Health Organization. Corona virus overview. WHO. Available at: https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_1 . Accessed on 4\/5\/2020."},{"key":"5698_CR2","unstructured":"Worldometers. COVID-19 CORONAVIRUS PANDEMIC. Available at: https:\/\/www.worldometers.info\/coronavirus\/ . Accessed 8 Aug 2020."},{"key":"5698_CR3","unstructured":"World Health Organization Europe 2019-nCoV outbreak is an emergency of international concern: httsp:\/\/www.euro.who.int\/en\/health-topics\/health emergencies\/internationalhealth-regulations\/news\/news\/2020\/2\/2019-ncov-outbreakis-an-emergency-of-international-concern; (Accessed February 22, 2020)."},{"issue":"20","key":"5698_CR4","first-page":"30152","volume":"S1473\u20133099","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020;S1473\u20133099(20):30152\u20133 Published Online, March 5, 2020, https:\/\/doi.org\/10.1016.","journal-title":"Lancet Infect Dis"},{"key":"5698_CR5","doi-asserted-by":"crossref","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615.","DOI":"10.1016\/j.tmaid.2020.101615"},{"key":"5698_CR6","doi-asserted-by":"publisher","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends. 2020. https:\/\/doi.org\/10.5582\/bst.2020.01047.","DOI":"10.5582\/bst.2020.01047"},{"key":"5698_CR7","doi-asserted-by":"publisher","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787.","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"5698_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin YS, Leneva IA, P\u00e9cheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15:997\u20131005.","journal-title":"Curr Med Chem"},{"key":"5698_CR9","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/JVI.02077-15","volume":"90","author":"E-I P\u00e9cheur","year":"2016","unstructured":"P\u00e9cheur E-I, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, et al. The synthetic antiviral drug Arbidol inhibits globally prevalent pathogenic viruses. J Virol. 2016;90:3086\u201392.","journal-title":"J Virol"},{"key":"5698_CR10","doi-asserted-by":"publisher","first-page":"112687","DOI":"10.1016\/j.ejmech.2020.112687","volume":"205","author":"LU Zheng","year":"2020","unstructured":"Zheng LU, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem. 2020;205:112687. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112687.","journal-title":"Eur J Med Chem"},{"key":"5698_CR11","doi-asserted-by":"publisher","unstructured":"Bernheim A , Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Feb 20 2020 https:\/\/doi.org\/10.1148\/radiol.2020200463.","DOI":"10.1148\/radiol.2020200463"},{"key":"5698_CR12","first-page":"267","volume-title":"Medical Statistics: A Textbook for the Health Sciences Wiley, 4th Edition","author":"MJ Campbell","year":"2007","unstructured":"Campbell MJ, Machin D, Walters SJ. Medical Statistics: A Textbook for the Health Sciences Wiley, 4th Edition; 2007. Sample size issues. p. 267."},{"issue":"4","key":"5698_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4155\/tde-2020-0035","volume":"11","author":"H Amawi","year":"2020","unstructured":"Amawi H, Abu Deiab GI, AA DK, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020;11(4):245\u201368.","journal-title":"Ther Deliv"},{"key":"5698_CR14","doi-asserted-by":"crossref","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Szyma\u0144ska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, et al. Arbidol and other low-molecular-weight drugs that inhibit lassa and ebola viruses. J Virol. 2019;93(8):e02185-18.","DOI":"10.1128\/JVI.02185-18"},{"issue":"1","key":"5698_CR15","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1038\/s41598-018-27224-4","volume":"8","author":"SL Fink","year":"2018","unstructured":"Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The antiviral drug Arbidol inhibits Zika virus. Sci Rep. 2018;8(1):8989.","journal-title":"Sci Rep"},{"issue":"4","key":"5698_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/jmv.25358","volume":"91","author":"IA Leneva","year":"2019","unstructured":"Leneva IA, Falynskova IN, Makhmudova NR, Poromov AA, Yatsyshina SB, Maleev VV. Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study. J Med Virol. 2019;91(4):588\u201397.","journal-title":"J Med Virol"},{"key":"5698_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antivir Res. 2014;107:84\u201394.","journal-title":"Antivir Res"},{"issue":"3","key":"5698_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11596-020-2203-3","volume":"40","author":"JN Zhang","year":"2020","unstructured":"Zhang JN, Wang WJ, Peng B, Peng W, Zhang YS, Wang YL, et al. Potential of Arbidol for post-exposure prophylaxis of COVID-19 transmission: a preliminary report of a retrospective cohort study. Curr Med Sci. 2020;40(3):480\u20135.","journal-title":"Curr Med Sci"},{"key":"5698_CR19","doi-asserted-by":"crossref","unstructured":"Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI). MedRxiv. 2020.","DOI":"10.1101\/2020.03.19.20038984"},{"issue":"1","key":"5698_CR20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","volume":"81","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21\u2013e3.","journal-title":"J Infect"},{"key":"5698_CR21","doi-asserted-by":"publisher","unstructured":"Zheng H, Tan J, Zhang X, Luo A, Wang L, Zhu W, et al. Impact of sex and age on respiratory support and length of hospital stay among 1792 patients with COVID-19 in Wuhan, China. BJA. 2020. https:\/\/doi.org\/10.1016\/j.bja.2020.07.001.","DOI":"10.1016\/j.bja.2020.07.001"},{"issue":"1","key":"5698_CR22","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jinf.2020.04.008","volume":"81","author":"X Liu","year":"2020","unstructured":"Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81(1):e95\u2013e7.","journal-title":"J Infect"},{"issue":"1","key":"5698_CR23","doi-asserted-by":"publisher","first-page":"0","DOI":"10.3866\/PKU.DXHX202002013","volume":"49","author":"K Xu","year":"2020","unstructured":"Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue bao Yi xue ban. 2020;49(1):0.","journal-title":"Zhejiang da xue bao Yi xue ban"},{"issue":"1","key":"5698_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"L Deng","year":"2020","unstructured":"Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1\u20135.","journal-title":"J Infect"},{"key":"5698_CR25","doi-asserted-by":"publisher","unstructured":"Liu Q, Fang X, Tian L, Chen X, Chung U, Wang K, et al. The effect of Arbidol Hydrochloride on reducing mortality of COVID-19 patients: a retrospective study of real world date from three hospitals in Wuhan. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.11.20056523.","DOI":"10.1101\/2020.04.11.20056523"},{"key":"5698_CR26","unstructured":"Chen J, Ling Y, Xi X, Liu P, Li F, Li T, et al. Efficacies of lopinavir\/ritonavir and arbidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis. 2020;38(0):E008."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05698-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T11:05:32Z","timestamp":1607943932000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05698-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5698"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05698-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by ethics committee of IUMS (IR.IUMS.RCT.1399.090). All patients signed informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have \u201cno competing interests\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"954"}}